Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Inv. presentation
ARS Pharmaceuticals, Inc. (SBTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates ARS continues engagement with U.S. FDA on final labeling and post-marketing commitments for the neffy® new drug application; PDUFA target action date set for September 19, 2023 Ended second quarter with $252.2 million in cash, cash equivalents and short-term investments; well-capitalized to support anticipated launch of neffy in the U.S. and an expected operating runway of at least three years SAN DIEGO – August 10, 2023 -ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the second quarter of 2023. &#x2..."
08/01/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/28/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 8-K Investor presentation
Docs: "Corporate Presentation"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions , Including Anaphylaxis New Drug and Marketing Authorization Applications for neffy Under Review with FDA and EMA, Respectively; FDA PDUFA Target Action Date Anticipated mid-2023 $264.5 Million in Cash, Cash Equivalents and Short-term Investments to Support Operating Runway for the Next Three Years, Including the Planned Commercialization of neffy in the United States SAN DIEGO – May 15, 2023 -ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead t..."
05/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company comments to FDA Briefing Document",
"Company comments to FDA Briefing Document"
05/08/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA and EMA; FDA PDUFA Target Action Date Anticipated in Mid-2023 Strong Financial Position with $274.4 Million in Cash, Cash Equivalents and Short-term Investments to Support Operating Runway for the Next Three Years SAN DIEGO – March 23, 2023 - ARS Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today highlighted recent progress and reported fourth quarter and full year 2022 financial results. “This is an incredibly exciting ti..."
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Company Presentation",
"Company Presentation"
02/22/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement  Interactive Data
02/14/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "Company Presentation",
"Company Presentation"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 5.7% stake in ARS PHARMACEUTICALS INC
01/17/2023 8-K/A Quarterly results
01/17/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
12/09/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
11/30/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/21/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
11/18/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
11/18/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
11/18/2022 SC 13D Lowenthal Richard E reports a 7.9% stake in ARS Pharmaceuticals, Inc.
11/18/2022 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
11/08/2022 8-K Entered into consulting agreement
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC.,",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation of Silverback Therapeutics, Inc",
"Certificate of Merger",
"Warrant to purchase stock issued to Silicon Valley Bank, as amended on December 7, 2020",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Confidential LICENSE AGREEMENT between ARS PHARMACEUTICALS, INC. and AEGIS THERAPEUTICS, LLC",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Confidential COLLABORATION AND DISTRIBUTION AGREEMENT",
"Cover Page Interactive Data File (embedded within the Inline XBRL document",
"CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL.",
"9. Section 409A. It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1, 1.409A-1 and 1.409A-1, and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement will be construed in a manner that complies with Section 409A. For purposes of Code Section 409A ), Executive's right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. ..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy